Featuring: YouYang Zhao, PhD
Northwestern Medicine scientists developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which line blood vessel walls.
Published in Cell Reports, this is the first time that vascular endothelial cells could be reached for genome editing, since the usual way to deliver CRISPR/Cas9 – through a virus – does not work for this cell type, according to YouYang Zhao, PhD, professor of Pediatrics in the Division of Critical Care and senior author of the study.
“The nanoparticle we developed is a powerful new delivery system for genome editing in vascular endothelial cells, and could be used to treat many diseases, including acute respiratory distress syndrome from severe COVID-19,” said Zhao, who is a member of the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago. “With this nanoparticle we can introduce genes to inhibit vascular injury or promote vascular repair, correct gene mutations and turn genes on or off to restore normal function. It also allows us to edit multiple genes at the same time. This is an important advance for treating any disease caused by endothelial dysfunction.”
Endothelial dysfunction is at the root of many diseases, such as coronary artery disease, stroke, bronchopulmonary dysplasia and pulmonary artery hypertension. Zhao explained that genome editing in endothelial cells could even treat cancers by cutting off the blood supply to the tumor or blocking cancer metastasis.
At this stage, Dr. Zhao and colleagues achieved excellent results in a mouse model. The nanoparticle carrying CRISPR/Cas9 plasmid DNA was introduced via a one-time IV injection and required a few days to be effective. Preclinical testing will be necessary before clinical trials can begin.
“Our nanoparticle delivery system for genome editing and transgene expression also is a huge advance for cardiovascular research,” Zhao added.
Zhao is also a professor of Medicine in the Division of Pulmonary and Critical Care and of Pharmacology.
Research at Ann & Robert H. Lurie Children’s Hospital of Chicago is conducted through the Stanley Manne Children’s Research Institute. The Manne Research Institute is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children’s is ranked as one of the nation’s top children’s hospitals by U.S. News & World Report. It is the pediatric training ground for Northwestern University Feinberg School of Medicine. Last year, the hospital served more than 220,000 children from 48 states and 49 countries.
This article was originally published in the Northwestern University Feinberg School of Medicine News Center on January 14, 2022.
YouYang Zhao, PhD, professor of Pediatrics in the Division of Critical Care and member of the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, was senior author of the study published in Cell Reports.
Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients.